Biomedical Engineering Reference
In-Depth Information
Light Source
(Wavelength
in nm)
MAL-PDT Study
Design
Incubation
Period (hr)
# Lesions Treated
(# Patients)
Reference
Location
Response Rate
Follow-up (mo)
Soler (162) (2001)
1× MAL-PDT
(lesion
preparation)
Face, scalp, trunk,
and extremities
Mean 4 occluded
82 Thin nBCC
(<2 mm thick-
ness), 86 thick
nBCC (>2 mm)
Broadband
halogen light
(570-670 nm)
light dose of
50-200 J/cm
2
,
light intensity of
100-180 mW/cm
2
Thin nBCC: 93%
CR and thick
nBCC: 86% CR
after 3 mo, 7% of
thin nBCC and
14% of thick
nBCC relapsed at
35 mo
24-48
Horn (143) (2003)
MAL-PDT
“diffi cult-to-treat”
BCC (European
trial)
2× MAL-PDT
retreated after
3 mo if necessary
(lesion
preparation)
Face, scalp, neck,
trunk, and
extremities
3, Occluded
52 nBCC
Red light
(570-670 nm),
dose of 75 J/cm
2
,
light intensity of
50-200 mW/cm
2
75% CR after
3 mo (histologic
control); 14%
recurrence at
24 mo
24
Rhodes (159) (2004)
2× MAL-PDT
(7 days apart) vs.
surgery (lesion
preparation),
retreatment after
3 mo if required
Face, scalp, neck,
trunk, and
extremities
3, Occluded
105 nBCC
(53 treated
with MAL-PDT)
Red light
(570-670 nm),
dose of 75 J/cm
2
,
light intensity of
50-200 mW/cm
2
MAL-PDT:
91% CR vs.
Surgery: 98%
3 mo after last
treatment, NR, or
recurrence after
24 mo: 19% in
the MAL-PDT vs.
4% in the surgery
group
24
Vinciullo (149) (2005)
MAL-PDT “diffi cult
to treat” BCC
(Australian trial)
2× MAL-PDT
retreated after
3 mo if necessary
(lesion
preparation)
Face, scalp, neck,
trunk, and
extremities
3, Occluded
36 nBCC
Red light
(570-670 nm),
dose of 75 J/cm
2
,
light intensity of
50-200 mW/cm
2
82% CR at 3 mo,
67% at 24 mo
24
(
Continued
)
